TY - JOUR
T1 - Developing valid and reliable health utilities in irritable bowel syndrome
T2 - Results from the IBS PROOF cohort
AU - Spiegel, Brennan
AU - Harris, Lucinda
AU - Lucak, Susan
AU - Mayer, Emeran
AU - Naliboff, Bruce
AU - Bolus, Roger
AU - Esrailian, Eric
AU - Chey, William D.
AU - Lembo, Anthony
AU - Karsan, Hetal
AU - Tillisch, Kirsten
AU - Dulai, Gareth
AU - Talley, Jennifer
AU - Chang, Lin
PY - 2009/8
Y1 - 2009/8
N2 - OBJECTIVES: A utility is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.METHODS:We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohorta longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.RESULTS:There were 257 patients (79% women; age43±15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P < 0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r0.31; P<0.01), IBSSS (r0.36; P<0.01), IBS-QOL (r0.36; P<0.01), CDC-4 (r0.44; P<0.01), WPAI presenteeism (r0.16; P<0.01), abdominal pain (r0.43; P<0.01), and distension (r0.18; P<0.01). The utilities in patients reporting considerable relief of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P<0.02).CONCLUSIONS:EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.
AB - OBJECTIVES: A utility is a measure of health-related quality of life (HRQOL) that ranges between 0 (death) and 1 (perfect health). Disease-targeted utilities are mandatory to conduct cost-utility analyses. Given the economic and healthcare burden of irritable bowel syndrome (IBS), cost-utility analyses will play an important role in guiding health economic decision-making. To inform future cost-utility analyses in IBS, we measured and validated the IBS utilities.METHODS:We analyzed data from Rome III IBS patients in the Patient Reported Observed Outcomes and Function (PROOF) Cohorta longitudinal multi-center IBS registry. At entry, the patients completed a multi-attribute utility instrument (EuroQOL), bowel symptom items, IBS severity measurements (IBS Severity Scale (IBSSS), Functional Bowel Disease Severity Index (FBDSI)), HRQOL indexes (IBS quality-of-life instrument (IBS-QOL), Center for disease control-4 (CDC-4)), and the Worker Productivity Activity Index for IBS (WPAI). We repeated assessments at 3 months.RESULTS:There were 257 patients (79% women; age43±15 years) at baseline and 85 at 3 months. The mean utilities in patients with severe vs. non-severe IBS were 0.70 and 0.80, respectively (P < 0.001). There were no differences in utilities among IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed IBS (IBS-M) subgroups. EuroQOL utilities correlated with FBDSI (r0.31; P<0.01), IBSSS (r0.36; P<0.01), IBS-QOL (r0.36; P<0.01), CDC-4 (r0.44; P<0.01), WPAI presenteeism (r0.16; P<0.01), abdominal pain (r0.43; P<0.01), and distension (r0.18; P<0.01). The utilities in patients reporting considerable relief of symptoms at 3 months vs. those without considerable relief were 0.78 and 0.73, respectively (P<0.02).CONCLUSIONS:EuroQOL utilities are valid and reliable in IBS. The utility of severe IBS (0.7) is similar to Class III congestive heart failure and rheumatoid arthritis. These validated utilities can be employed in future IBS cost-utility analyses.
UR - http://www.scopus.com/inward/record.url?scp=68349141680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68349141680&partnerID=8YFLogxK
U2 - 10.1038/ajg.2009.232
DO - 10.1038/ajg.2009.232
M3 - Article
C2 - 19491835
AN - SCOPUS:68349141680
SN - 0002-9270
VL - 104
SP - 1984
EP - 1991
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 8
ER -